New research is being presented at TCT 2014, the Transcatheter Cardiovascular Therapeutics annual meeting, from September 13 to 17, in Washington, DC.


Meeting Highlights

Managing In-Stent Restenosis

Embolic Protection During TAVI

Comparing TAVR to Surgery in Intermediate-Risk Patients


News From TCT 2014

Cap and Lead Pelvic Drape Reduce Radiation Exposure to Operators in PCI

No MACE Benefit With Prasugrel in ACS

“Sham” Renal Denervation Defended

Six Months of DAPT Offers SECURITY in Low-Risk PCI

PFO Closure Fails Anew in Migraine

FDA Town Hall Paves Way for New Approval Strategies

Renal Denervation Misses in Mildly Hypertensive Patients

Female Interventionalists ‘Very Rare,’ Work in Isolation

No Harm, No Foul With Triple Therapy

Light From BRIGHT: More Fuel for Bivalirudin-Heparin Debate

Reassuring Data on Use of DAPT and Anticoagulation

Rx for Bifurcation Lesions — Hold the Stenting

Bioresorbable Scaffold Safe But Not Spectacular

Dead or Treading Water: Experts Debate Future of Renal Denervation for Resistant Hypertension

No Deaths With Mild/Moderate Paravalvular Leaks: CoreValve Extreme Risk at Two Years

St Jude Issues Worldwide ‘Pause’ on Portico TAVR Implants

CoreValve TAVR Ups Survival, Has $$$ Value

Sapien Valve Survival Benefit Durable at 5 Years

Vascular-Closure Devices as Good as Hands-on After Diagnostic Coronary Angiography

TAVR Deaths at Five Years in PARTNER: Sobering and Remarkable

DC Meeting Highlights Iterative Change


More From TCT 2014


About TCT


Program Agend

Hillary Clinton Keynote Address

Virtual TCT

TCT in 3

Hands-on TAVR Imaging

Visual Interactive Technology Center

Late-Breaking Clinical Trials and First Report Investigations

Challenging Cases


FDA Town Hall Meeting

Nurse & Technologist Symposium

Satellite Symposia

Live Case Sites

Fellows Track

Endovascular Course

About Washington, DC


Travel & Airfare

Air & Ground Transportation

Shuttle Schedule